CG Oncology CGON Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Other Operating Assets at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingAssets.
The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about CG Oncology's increase (decrease) in other operating assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CG Oncology's increase (decrease) in other operating assets?
- CG Oncology (CGON) reported increase (decrease) in other operating assets of $998K in Q1 2026.
- How has CG Oncology's increase (decrease) in other operating assets changed year-over-year?
- CG Oncology's increase (decrease) in other operating assets increased by 2751.4% year-over-year, from $35K to $998K.
- What is the long-term trend for CG Oncology's increase (decrease) in other operating assets?
- Over 2 years (2023 to 2025), CG Oncology's increase (decrease) in other operating assets has grown at a 1011.5% compound annual growth rate (CAGR), from -$13K to $1.61M.
- What does increase (decrease) in other operating assets mean?
- This captures the net change in miscellaneous assets that are not classified as loans, securities, or property, plant, and equipment. It often includes items like accrued interest receivables, prepaid expenses, and other short-term operational assets.